Sequence
Sequence positions itself as the "clinical-first" GLP-1 telehealth provider. Founded by obesity medicine specialists, the platform emphasizes board-certified clinicians, insurance-first prescribing, and a medically rigorous approach compared to most direct-to-consumer competitors. Their model prioritizes getting patients onto brand-name FDA-approved medications through insurance rather than defaulting to compounded alternatives.
Overview
- Consultation Model
- Hybrid
- Headquarters
- New York, NY
- Shipping
- 3-5 business days
- Lab Testing
- No
- Prescriber Info
- Licensed healthcare providers evaluate patients and prescribe based on clinical eligibility.
- Founded
- 2021
Pros
- Founded by obesity medicine specialists
- Insurance-first approach can save patients hundreds per month on brand-name GLP-1 medications
- Video consultations with experienced clinicians, not just questionnaire-based async reviews
- Prior authorization and insurance appeals support included in membership
- Personalized titration managed through follow-up video visits
Cons
- Higher total cost for cash-pay patients
- The $99/month membership is charged on top of medication costs (unlike all-inclusive platforms)
- No published independent outcomes data for their patient population
- Insurance navigation success varies
- Less established brand than Hims or Ro
Pricing
| Medication | Dose | Price | Billing |
|---|---|---|---|
| liraglutide | 0.6-3mg/day | $149 | monthly |
| tirzepatide | 2.5-15mg/week | $149 | monthly |
| semaglutide | 0.25-2.4mg/week | $149 | monthly |